Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)

Summary

Evaluation of spironolactone, a well-known cardiological treatment, in patients with rheumatoid arthritis (RA). The hypothesis is that spironolactone, through its anti-inflammatory and anti-fibrosis actions, decreases RA's activity. The primary objective is to assess the efficacy of spironolactone on RA activity by evaluating the proportion of patients achieving DAS28-CRP \< 3.2 at 3 months (comparison between spironolactone and placebo arms). CRP (C reactive protein)

Eligibility

Inclusion Criteria:

* patients 18 years of age and over
* diagnosis of RA according to EULAR/ACR 2010 classification criteria
* active RA: DAS28-CRP ≥ 3.2
* insufficient response despite a stable DMARD treatment (cDMARD/tsDMARD(targeted synthetic DMARD)/bDMARD) ≥ 12 weeks
* stable dose of corticosteroids for at least 4 weeks prior to inclusion
* patient able to understand the objectives and risks of the study and to provide a written informed consent to participate in the study, dated and signed before initiating any trial-related procedure
* patient having been informed about the results of the preliminary medical visit
* if woman of childbearing, they should have no desire to procreate for the duration of their participation in the study, agreeing to use an effective contraception method\* during the study and until 5 days following the last visit or last dose of treatment in case of early stop; acceptable birth control methods:

  * progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
  * male or female condom with or without spermicide\*
  * cap, diaphragm or sponge with spermicide\*

    * a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods) are also considered acceptable, but not highly effective, birth control methods
* affiliation to a social security regime

Exclusion Criteria:

* severe or acute renal insufficiency, defined by eGFR \< 30 mL/min
* hyperkalemia, with K+ \> 5,1 mmol/L
* end-stage liver failure, cirrhosis
* hypersensitivity to the active ingredients or intolerance to any of the excipients including lactose
* Addison's disease
* patient currently being treated with spironolactone, or previous spironolactone treatment in the last 3 months
* concomitant treatment with:

  * mitotane,
  * other potassium-sparing diuretics (alone or in combination) such as amiloride, potassium canrenoate, eplerenone, triamterene
* other inflammatory arthritis except associated Sjögren's syndrome
* pregnancy (women of childbearing potential : positive blood pregnancy test at the inclusion visit (V0))
* breastfeeding
* participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment or still under the exclusion period
* unwillingness or incapacity to adhere to study protocol (language barriers, cognitive disorders, etc.).
* subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
* patient who cannot be followed for 6 months
* patient over the age of legal majority who are protected, or deprived of liberty by judicial or administrative decision (vulnerable subjects)

Conditions2

Interventions1

Related trials

• Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD — Hospices Civils de Lyon
• Fibrosis and the Fontan — Children's Hospital of Philadelphia
• Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism? — University of Virginia
• Hyperandrogenemia and Altered Day-night LH Pulse Patterns — University of Virginia

Browse More Trials